At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Aug 20, 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012

Aug 7, 2014
Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates

View all »Events & Presentations

Aug 20, 2014 at 8:00 AM ET
Phase III Fabry Monotherapy Study Results Conference Call

Aug 7, 2014 at 5:00 PM ET
Amicus 2Q Results Conference Call and Webcast

Copyright © 2014 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy